The use of gonadotropins and biosimilars in ART treated cycles

Currently a variety of urinary and recombinant versions of gonadotropins are widely available and in use in IVF treatment. Numerous studies have tried to establish whether there is any clinical difference in terms of efficacy (mainly live birth rate) and/or safety (mainly risk of OHSS) between these modalities. Results have been inconclusive and somewhat conflicting. In light of this controversy, the following survey is due to assess the opinion of practicing clinicians and their rationale behind their decision-making on this topic. The survey results reflecting the collective wisdom of IVF experts.